Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs IQVIA Holdings Inc. Common Stock (IQV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs IQVIA Holdings Inc. Common Stock — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while IQVIA Holdings Inc. Common Stock trades at $261.7 (market cap $42.91B). The key difference: IQVIA Holdings Inc. Common Stock is the larger of the two by market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while IQVIA Holdings Inc. Common Stock pays none. Which is the better fit depends on your goals.
| GEHC | IQV | |
|---|---|---|
Market Cap | $31.07B | $42.91B |
Volume | 3,443,020 | 1,333,456 |
Sector | Health | Health |
52-Week High | $88.16 | $275.02 |
52-Week Low | $59.48 | $156.66 |
Enterprise Value | $39.53B | $57.07B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 6 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About IQVIA Holdings Inc. Common Stock
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →
